Who makes Glurenorm®?

Glurenorm® is developed by Novo Nordisk A/S.

What development phase is Glurenorm® in?

Glurenorm® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Glurenorm®

Novo Nordisk A/S · FDA-approved active Small molecule Quality 0/100

Glurenorm®, marketed by Novo Nordisk A/S, is a diabetes treatment with a well-established presence in the market. The drug's key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.

At a glance

Generic name	Glurenorm®
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glurenorm® CI brief — competitive landscape report
Glurenorm® updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI